Andrew John Partridge

CIK 1758838 · Chief Growth Officer · last filed 2026-10-07

Andrew John Partridge is a Chief Growth Officer who has filed 8 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing shows the insider sold $1.2M of GRAL on Oct 7, 2026. Across all open-market trades the lifetime net is −$1.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $20.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$20.25M

Companies

Total Filings

Lifetime Open-Market Net

-$1.39M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

GRAL price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address

C/O CENTREXION THERAPEUTICS CORPORATION
200 STATE STREET
BOSTON, MA 02109

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
GRAL	Chief Growth Officer	155,865	$129.93	$20.25M	-$1.15M	1	2026-10-07
GRAIL, Inc. (GRALV) Delisted	Chief Growth Officer	163,738	—	—	-$91.1K	1	2026-06-05
Turning Point Therapeutics, Inc. (TPTX) Delisted	EVP & Chief Commercial Officer	38,361	$76.01	$2.92M	-$148.0K	4	2022-02-11

Recent Filings

8 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-10-07	GRAL	Sell (S)	−7,873	-$1.15M	EDGAR
2026-10-05	GRAL	Notice (144)	−7,873	-$1.15M	EDGAR
2026-06-05	GRAIL, Inc. (GRALV) Delisted	Sell (S)	−1,491	-$91.1K	EDGAR
2026-06-03	GRAL	Notice (144)	−1,705	-$104.2K	EDGAR
2022-02-11	Turning Point Therapeutics, Inc. (TPTX) Delisted	Mixed	+16,062	-$8.0K	EDGAR
2021-07-15	Turning Point Therapeutics, Inc. (TPTX) Delisted	Sell (S)	−1,869	-$140.0K	EDGAR
2021-02-10	Turning Point Therapeutics, Inc. (TPTX) Delisted	Grant (A)	+2,136	$0	EDGAR
2020-07-14	Turning Point Therapeutics, Inc. (TPTX) Delisted	Grant (A)	+21,500	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.